Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/11/2022 | $5.00 → $2.00 | Buy → Neutral | HC Wainwright & Co. |
| 3/3/2022 | $10.00 → $2.00 | Outperform → Market Perform | SVB Leerink |
| 3/1/2022 | $23.00 → $1.50 | Buy → Hold | Jefferies |
| 1/24/2022 | $15.00 → $10.00 | Outperform | SVB Leerink |
| 12/20/2021 | $25.00 → $15.00 | Outperform | SVB Leerink |
| 12/15/2021 | $20.00 | Buy | HC Wainwright & Co. |
| 10/6/2021 | $20.00 → $18.00 | Buy | Goldman Sachs |
WATERTOWN, Mass., Dec. 27, 2022 /PRNewswire/ -- Disc Medicine, Inc. ("Disc"), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that the U.S. Food and Drug Administration ("FDA") granted Orphan Drug Designation to bitopertin for the treatment of erythropoietic protoporphyria ("EPP"). Bitopertin is an investigational oral, selective inhibitor of glycine transporter 1 ("GlyT1") designed to modulate heme biosynthesis, and has been shown in preclinical studies to reduce accumulation of protoporphyrin IX ("PPIX"), the toxic metabolite that causes dise
WATERTOWN, Mass., Dec. 13, 2022 /PRNewswire/ -- Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients living with serious hematologic diseases, presented five posters spanning several of its hematology programs at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition held in New Orleans, LA. "Disc Medicine continues to make considerable progress towards the development of potentially first-in-class therapeutic candidates for hematologic disorders," said John
CAMBRIDGE, Mass., Nov. 3, 2022 /PRNewswire/ -- Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that five abstracts related to several of its hematology programs have been accepted for poster presentation at the upcoming 64th American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held in New Orleans, LA on December 10-13, 2022. "We are pleased to have five abstracts selected for presentat
HC Wainwright & Co. downgraded Gemini Therapeutics from Buy to Neutral and set a new price target of $2.00 from $5.00 previously
SVB Leerink downgraded Gemini Therapeutics from Outperform to Market Perform and set a new price target of $2.00 from $10.00 previously
Jefferies downgraded Gemini Therapeutics from Buy to Hold and set a new price target of $1.50 from $23.00 previously
4 - Disc Medicine, Inc. (0001816736) (Issuer)
3 - Disc Medicine, Inc. (0001816736) (Issuer)
4 - Disc Medicine, Inc. (0001816736) (Issuer)
8-K - Disc Medicine, Inc. (0001816736) (Filer)
144 - Disc Medicine, Inc. (0001816736) (Subject)
144 - Disc Medicine, Inc. (0001816736) (Subject)
Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today provided a corporate update announcing a leadership transition, strategic evaluation and corporate restructuring. The Board of Directors has appointed Georges Gemayel, Ph.D., the Company's current Executive Chair, as interim President and Chief Executive Officer to succeed Jason Meyenburg, who has transitioned from his roles as President, CEO and Director and will continue to serve as an advisor to the Company. Additionally, the Company has initiated a process to evaluate strategic alternatives in order
Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced the appointment of Georges Gemayel, Ph. D., as the Chair of the Company's Board of Directors. "I am pleased to welcome Georges to Gemini's Board of Directors during this important time in our Company's maturation, as we advance our lead program into the next stages of clinical development," said Jason Meyenburg, Chief Executive Officer of Gemini Therapeutics. "Georges' broad management experience and proven track record of commercial and product development success wi
Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced the appointment of Samuel Barone, M.D., as Gemini's Chief Medical Officer, effective immediately. "We are thrilled to welcome Sam to Gemini as Chief Medical Officer, where he will bring his expertise as a board-certified ophthalmologist specializing in the treatment of retinal and macular diseases," said Jason Meyenburg, Chief Executive Officer of Gemini Therapeutics. "As we continue to advance our clinical pipeline, we will benefit tremendously from his two-plus deca
SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)
SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)
SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)